These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10713679)

  • 1. Mouse models for breast cancer.
    Hennighausen L
    Oncogene; 2000 Feb; 19(8):966-7. PubMed ID: 10713679
    [No Abstract]   [Full Text] [Related]  

  • 2. Transforming growth factor alpha and mouse models of human breast cancer.
    Humphreys RC; Hennighausen L
    Oncogene; 2000 Feb; 19(8):1085-91. PubMed ID: 10713694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
    Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A
    Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.
    Reddy KB; McGowen R; Schuger L; Visscher D; Sheng S
    Oncogene; 2001 Oct; 20(45):6538-43. PubMed ID: 11641778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular insights into breast cancer from transgenic mouse models.
    Dickson RB; Gottardis MM; Merlino GT
    Bioessays; 1991 Nov; 13(11):591-6. PubMed ID: 1663341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways.
    Callahan R; Smith GH
    Oncogene; 2000 Feb; 19(8):992-1001. PubMed ID: 10713682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary tumorigenesis and metastasis in transgenic mice.
    Webster MA; Muller WJ
    Semin Cancer Biol; 1994 Feb; 5(1):69-76. PubMed ID: 8186390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats.
    Davies BR; Warren JR; Schmidt G; Rudland PS
    Biochem Soc Symp; 1998; 63():167-84. PubMed ID: 9513721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
    Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
    Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mouse models of mammary tumorigenesis.
    Cardiff RD; Muller WJ
    Cancer Surv; 1993; 16():97-113. PubMed ID: 8394206
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse models and breast cancer.
    Robinson A
    CMAJ; 1995 Oct; 153(8):1123-4. PubMed ID: 7553521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
    Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes involved in breast cancer progression: analysis of global changes in gene expression or retroviral tagging?
    Schmidt EV
    Am J Pathol; 2002 Dec; 161(6):1973-7. PubMed ID: 12466111
    [No Abstract]   [Full Text] [Related]  

  • 17. Contributions of mouse biology to breast cancer research.
    Cardiff RD; Bern HA; Faulkin LJ; Daniel CW; Smith GH; Young LJ; Medina D; Gardner MB; Wellings SR; Shyamala G; Guzman RC; Rajkumar L; Yang J; Thordarson G; Nandi S; MacLeod CL; Oshima RG; Man AK; Sawai ET; Gregg JP; Cheung AT; Lau DH
    Comp Med; 2002 Feb; 52(1):12-31. PubMed ID: 11900409
    [No Abstract]   [Full Text] [Related]  

  • 18. A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer.
    Hollern DP; Yuwanita I; Andrechek ER
    Oncogene; 2013 Mar; 32(10):1296-304. PubMed ID: 22525269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
    Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
    Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice.
    Rose-Hellekant TA; Sandgren EP
    Oncogene; 2000 Feb; 19(8):1092-6. PubMed ID: 10713695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.